Medico Remedies Limited has reported its audited standalone financial results for the financial year ended March 31, 2026. The company's board approved the results during a meeting held on May 21, 2026. M/s. Shah Shroff & Associates, the statutory auditors, issued an audit report with an unmodified opinion on the financial statements.

For the full year, the company recorded a net profit of ₹1,311.52 lakh, an increase from ₹1,009.32 lakh in the previous year. Revenue from operations grew to ₹20,637.73 lakh compared to ₹15,094.06 lakh in FY25. Total income for the year stood at ₹21,231.08 lakh, up from ₹15,363.00 lakh in the prior year.

Financial Performance

The company's total expenses for FY26 amounted to ₹19,425.12 lakh, higher than the ₹14,012.63 lakh reported in the previous year. Profit before tax for the year was ₹1,805.96 lakh, compared to ₹1,350.37 lakh in FY25. The basic and diluted earnings per share (EPS) for the year were reported at ₹1.58, up from ₹1.22 in the corresponding period last year.

Quarterly Results

For the quarter ended March 31, 2026, medico remedies reported a net profit of ₹585.66 lakh. Revenue from operations for the quarter stood at ₹5,680.77 lakh, while total income was ₹5,968.16 lakh. Total expenses for the quarter were ₹5,136.23 lakh, resulting in a profit before tax of ₹831.92 lakh.

Financial Position

The company's total assets as of March 31, 2026, stood at ₹15,340.33 lakh, an increase from ₹11,979.93 lakh in the previous year. Total equity rose to ₹7,547.45 lakh from ₹6,246.89 lakh. Current assets increased significantly to ₹12,891.76 lakh, driven by higher trade receivables and inventories.

Cash Flow and Segment Reporting

Net cash flow from operating activities for the year was ₹587.42 lakh, compared to ₹489.21 lakh in the previous year. The company reported that it operates as a single operating segment. Geographical sales data for the quarter ended March 31, 2026, showed sales outside India at ₹5,364.29 lakh, while domestic sales were ₹274.48 lakh.

Medico Remedies Ltd has disclosed regulatory action taken by stock exchanges regarding alleged non-compliance with SEBI Listing Regulations, resulting in penalty payments to both NSE and BSE.

Regulatory Action Details

The pharmaceutical manufacturer received Show of Penalty (SoP) notices from both major Indian stock exchanges on 20th February 2026. The notices pertained to alleged non-compliance with Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Waiver Application Process

Following receipt of the penalty notices, Medico Remedies filed waiver applications with both exchanges on 24th February 2026. However, both applications were subsequently rejected by the respective exchanges.

Company Response and Compliance

The company has paid the requisite SoP fines to both BSE and NSE on 24th February 2026. Management confirmed that from 18th February 2026 onwards, the company is compliant with Regulation 6(1) of the SEBI (LODR) Regulations, 2015.

Impact Assessment

According to the company's disclosure, there is no material impact on financials, operations, or other activities of the company due to this regulatory action. The violation was described as an inadvertent oversight in compliance procedures.

Future Compliance Measures

The company acknowledged that the disclosure was inadvertently missed within prescribed timelines and has committed to ensuring that such unintended failures to disclose within prescribed timelines do not arise in future. This regulatory action serves as a reminder of the importance of strict adherence to listing regulation requirements for publicly traded companies.